3 reasons to buy this quality ASX 200 healthcare share today

A leading expert expects this outperforming ASX 200 healthcare share will keep running hot.

| More on:
Cropped shot of an attractive young female scientist working on her computer in the laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

ASX 200 healthcare share Healius Ltd (ASX: HLS) has materially outperformed the S&P/ASX 200 Index (ASX: XJO) over the past year.

Shares in the pathology and imaging provider are up 0.7% in afternoon trade on Wednesday, changing hands for $1.45 apiece.

This sees the Healius share price up 19.8% since this time last year, racing ahead of the 5.5% 12-month gains posted by the benchmark Aussie index.

And according to Red Leaf Securities' John Athanasiou, Healius is well-placed to keep outperforming in the year ahead (courtesy of The Bull).

Why this ASX 200 healthcare share is a buy

"Healius is a diagnostic pathology and imaging company," said Athanasiou, who has a buy recommendation on the ASX 200 healthcare share.

The first reason you may want to consider buying the stock is for the upcoming special dividend.

Athanasiou said:

The sale of Lumas Imaging to Affinity Equity Partners for $965 million will be completed on May 1, 2025. The company intends to pay a special fully franked dividend of about $300 million, or 41.3 cents a share.

Commenting on that divestment when it was first announced last September, Healius CEO Paul Anderson said, "The sale of Lumus is a positive outcome for Healius shareholders, our staff, patients and referrers."

Anderson added that, "The sale will provide Healius with both the resources and time to continue to improve our pathology operations and the scope to return cash to shareholders."

Which is the second reason Red Leaf Securities' Athanasiou is bullish on the outlook for the ASX 200 healthcare share.

He noted:

The company is focusing on strengthening its core pathology operations. Growth in test volumes, driven by an ageing population and increased demand for complex diagnostics, should support margin expansion – particularly as Healius invests in automation and artificial intelligence to reduce costs.

And the third reason you may want to add Healius to your ASX share portfolio is the government's ongoing Medicare indexation reform program, which is forecast to deliver some $900 million in additional benefits to Aussies in the upcoming year.

"The company is also well positioned to benefit from potential Medicare indexation reforms," Athanasiou said.

He concluded, "While short term earnings have been under pressure, the combination of capital returns, structural demand and efficiency gains present an attractive medium-term opportunity."

The ASX 200 healthcare share held its investor day presentation on 27 March.

Drilling into those efficiency gains on the day, the Motley Fool's James Mickleboro noted:

Healius has already identified $15 million to $20 million in cost savings – mainly from removing unallocated corporate expenses – and has several programs in place to reduce labour, consumables, and logistics costs across the network.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man in business suit carries box of personal effects
Healthcare Shares

Monash IVF shares jump 9% as CEO quits after second embryo incident

Two incidents at its clinics have cost this CEO his job.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Guess which ASX 200 stock turned $5,000 into $34,264 in just three years!

Investors have been piling into this ASX 200 stock for years, sending the share price soaring.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Cochlear shares sink 9% on guidance downgrade

Investors haven't responded positively to this update. Let's dig deeper into it.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Telix shares push higher on investor day update

This radiopharmaceuticals company has grand plans for the future.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

3 leading ASX healthcare shares with global reach

These 3 healthcare companies are having an outsized impact far beyond local markets.

Read more »

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Healthcare Shares

Macquarie tips more than 100% upside for this ASX All Ords healthcare stock

This company could be set to soar.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »